Jak2 - Janus kinase 2 Gene

Rattus norvegicus

Gene ID: 24514 | Gene type: protein coding

About Jak2

Primary_assembly 1: 226,995,334-227,054,189 forward strand.mRatBN7.2:CM026974.1

This gene has 2 transcripts (splice variants), 265 orthologues, 32 paralogues and is associated with 95 phenotypes. Biased expression in Thymus (RPKM 325.), Spleen (RPKM 258.4) and 9 other tissues.

Summary

Enables several functions, including Insulin Receptor substrate binding activity; protein C-terminus binding activity; and signaling receptor binding activity. Involved in several processes, including cell surface receptor signaling pathway; positive regulation of protein transport; and regulation of apoptotic process. Located in cytosol; euchromatin; and nucleolus. Is active in glutamatergic synapse and postsynapse. Used to study several diseases, including hyperuricemia; liver disease (multiple); non-alcoholic fatty liver disease; retinal detachment; and thrombocytosis. Biomarker of gastrointestinal system Cancer (multiple); heart disease; liver cirrhosis; and obesity. Human ortholog(s) of this gene implicated in several diseases, including gastrointestinal system Cancer (multiple); hematologic Cancer (multiple); hepatic vascular disease (multiple); inflammatory bowel disease (multiple); and lung non-small cell carcinoma (multiple). Orthologous to human JAK2 (Janus kinase 2). [provided by Alliance of Genome Resources, Apr 2022]

Jak2 Products(1)

mRNA	Protein	Name
NM_031514.1	NP_113702.1	tyrosine-protein kinase JAK2

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	Reference	Source
enables acetylcholine receptor binding	IPI IPI: Inferred from physical interaction	12244045	RGD
enables growth hormone receptor binding	IPI IPI: Inferred from physical interaction	10502458	RGD
enables insulin receptor substrate binding	IPI IPI: Inferred from physical interaction	15701573	RGD
enables peptide hormone receptor binding	IPI IPI: Inferred from physical interaction	11244571	RGD
enables phosphatidylinositol 3-kinase binding	IPI IPI: Inferred from physical interaction	15530849	RGD
enables protein binding	IPI IPI: Inferred from physical interaction	8912646	RGD
enables protein tyrosine kinase activity	IMP IMP: Inferred from mutant phenotype	15659221	RGD
enables type 1 angiotensin receptor binding	IPI IPI: Inferred from physical interaction	9287353	RGD

Biological Process GO Annotation	Evidence	Reference	Source
involved in axon regeneration	IMP IMP: Inferred from mutant phenotype	15716400	RGD
involved in cell surface receptor signaling pathway via JAK-STAT	IDA IDA: Inferred from direct assay	11064147	RGD
involved in growth hormone receptor signaling pathway via JAK-STAT	IDA IDA: Inferred from direct assay	11244571	RGD
involved in hormone-mediated signaling pathway	IDA IDA: Inferred from direct assay	11064147	RGD
involved in intrinsic apoptotic signaling pathway in response to oxidative stress	IMP IMP: Inferred from mutant phenotype	15659221	RGD
involved in modulation of chemical synaptic transmission	IDA IDA: Inferred from direct assay	22284190	RGD
involved in modulation of chemical synaptic transmission	IMP IMP: Inferred from mutant phenotype	22284190	RGD
involved in negative regulation of apoptotic process	IMP IMP: Inferred from mutant phenotype	22382519	RGD
involved in negative regulation of cardiac muscle cell apoptotic process	IMP IMP: Inferred from mutant phenotype	23796350	RGD
involved in negative regulation of cell-cell adhesion	IMP IMP: Inferred from mutant phenotype	15530849	RGD
involved in negative regulation of neuron apoptotic process	IMP IMP: Inferred from mutant phenotype	12244045	RGD
involved in nuclear receptor-mediated mineralocorticoid signaling pathway	IMP IMP: Inferred from mutant phenotype	15932931	RGD
involved in platelet-derived growth factor receptor signaling pathway	IMP IMP: Inferred from mutant phenotype	15948243	RGD
involved in positive regulation of DNA-binding transcription factor activity	IMP IMP: Inferred from mutant phenotype	15322111	RGD
involved in positive regulation of MAPK cascade	IMP IMP: Inferred from mutant phenotype	16567515	RGD
involved in positive regulation of apoptotic process	IMP IMP: Inferred from mutant phenotype	16269269	RGD
involved in positive regulation of cell activation	IMP IMP: Inferred from mutant phenotype	15256805	RGD
involved in positive regulation of cell differentiation	IMP IMP: Inferred from mutant phenotype	16514419	RGD
involved in positive regulation of cell migration	IMP IMP: Inferred from mutant phenotype	15530849	RGD
involved in positive regulation of cell population proliferation	IMP IMP: Inferred from mutant phenotype	16567515	RGD
involved in positive regulation of cytosolic calcium ion concentration	IMP IMP: Inferred from mutant phenotype	16597920	RGD
involved in positive regulation of epithelial cell apoptotic process	IMP IMP: Inferred from mutant phenotype	22777122	RGD
involved in positive regulation of growth factor dependent skeletal muscle satellite cell proliferation	IMP IMP: Inferred from mutant phenotype	23869758	RGD
involved in positive regulation of insulin secretion	IMP IMP: Inferred from mutant phenotype	16597920	RGD
involved in positive regulation of interleukin-1 beta production	IMP IMP: Inferred from mutant phenotype	16934228	RGD
involved in positive regulation of nitric oxide biosynthetic process	IMP IMP: Inferred from mutant phenotype	12595539	RGD
involved in positive regulation of nitric-oxide synthase biosynthetic process	IDA IDA: Inferred from direct assay	11536325	RGD
involved in positive regulation of protein import into nucleus	IMP IMP: Inferred from mutant phenotype	15530849	RGD
involved in positive regulation of vascular associated smooth muscle cell proliferation	IMP IMP: Inferred from mutant phenotype	23516544	RGD
involved in protein autophosphorylation	IMP IMP: Inferred from mutant phenotype	15530849	RGD
involved in regulation of nitric oxide biosynthetic process	IGI IGI: Inferred from genetic interaction	16055727	RGD
involved in regulation of postsynapse to nucleus signaling pathway	EXP EXP: Inferred from Experiment	22284190	RGD
involved in regulation of postsynapse to nucleus signaling pathway	IDA IDA: Inferred from direct assay	22284190	RGD
involved in response to amine	IEP IEP: Inferred from expression pattern	29486150	RGD
involved in response to hydroperoxide	IMP IMP: Inferred from mutant phenotype	15659221	RGD
involved in response to organic cyclic compound	IEP IEP: Inferred from expression pattern	29486150	RGD
involved in response to oxidative stress	IMP IMP: Inferred from mutant phenotype	16269269	RGD
involved in type II interferon-mediated signaling pathway	IDA IDA: Inferred from direct assay	11536325	RGD
involved in tyrosine phosphorylation of STAT protein	IMP IMP: Inferred from mutant phenotype	15659221	RGD

Cellular Component GO Annotation	Evidence	Reference	Source
located in euchromatin	IDA IDA: Inferred from direct assay	8756581	RGD
is active in glutamatergic synapse	EXP EXP: Inferred from Experiment	22284190	RGD
is active in glutamatergic synapse	IDA IDA: Inferred from direct assay	22284190	RGD
is active in glutamatergic synapse	IMP IMP: Inferred from mutant phenotype	22284190	RGD
is active in postsynapse	IDA IDA: Inferred from direct assay	22284190	RGD

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Jak2 Protein Structure

FERM_F1

FERM_F2

FERM_C_JAK2

SH2_Jak2

PTK_Jak2_rpt1

PTKc_Jak2_rpt2

0
200
400
600
800
1000
1132 a.a.

Protein Preferred Names

Protein Names

tyrosine-protein kinase JAK2

JAK-2

Janus kinase 2 (a protein tyrosine kinase)

Jak2 Protein-protein interaction Information

Type Cross Intra	Protein Name	Protein ID	Interactor	Interactor Species	Interactor ID	Detection Method	Reference
Intra	Jak2	Q62689	Ptpn11	Rattus norvegicus	P41499	Anti Bait CoIP	8912646

Cross: Cross-species interaction Intra: Intraspecies interaction

Related Agents

Approval

Bioactive Molecules (24)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-50856	Ruxolitinib	Inhibitor	99.99%	Yes
HY-40354	Tofacitinib	Inhibitor	99.99%	Yes
HY-19569	Upadacitinib	Inhibitor	99.98%	Yes
HY-15315	Baricitinib	Inhibitor	99.97%	Yes
HY-10409	Fedratinib	Inhibitor	99.87%	Yes
HY-50858	Ruxolitinib phosphate	Inhibitor	99.97%	Yes
HY-16379	Pacritinib	Inhibitor	99.93%	Yes
HY-40354A	Tofacitinib citrate	Inhibitor	99.91%	Yes
HY-18300	Filgotinib	Inhibitor	99.44%	Yes
HY-107429	Abrocitinib	Inhibitor	99.26%	Unkown
HY-19568	Peficitinib	Inhibitor	99.43%	Yes
HY-15315A	Baricitinib phosphate	Inhibitor	99.97%	Yes
HY-50867	Lestaurtinib	Inhibitor	99.17%	Unkown
HY-109053	Delgocitinib	Inhibitor	99.87%	Unkown
HY-10409A	Fedratinib hydrochloride hydrate	Inhibitor	99.92%	Yes
HY-13577A	Oclacitinib monomaleate	Inhibitor	99.63%	Unkown
HY-13577	Oclacitinib	Inhibitor	99.59%	Unkown
HY-50856S	Deuruxolitinib	Inhibitor	99.18%	Unkown
HY-18300A	Filgotinib maleate	Inhibitor	99.88%	Yes
HY-50859	Ruxolitinib sulfate	Inhibitor	/	Unkown
HY-19569A	Upadacitinib tartrate tetrahydrate	Inhibitor	/	Unkown
HY-19568A	Peficitinib hydrobromide	Inhibitor	/	Unkown
HY-16379A	Pacritinib hydrochloride	Inhibitor	/	Unkown
HY-19568B	Peficitinib hydrochloride	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (28)

Cat. No.	Product Name	Effect	Purity	Phase
HY-155785	MTP	Inhibitor	/	Phase 4
HY-10961	Momelotinib	Inhibitor	99.37%	Phase 3
HY-50514	AT9283	Inhibitor	99.67%	Phase 3
HY-15999	Cerdulatinib	Inhibitor	99.06%	Phase 3
HY-12469	Decernotinib	Inhibitor	99.91%	Phase 3
HY-112708	Brepocitinib	Inhibitor	99.97%	Phase 3
HY-13775	XL019	Inhibitor	99.65%	Phase 3
HY-10962	Momelotinib sulfate	Inhibitor	98.06%	Phase 3
HY-112724	Ivarmacitinib	Inhibitor	99.82%	Phase 3
HY-15999A	Cerdulatinib hydrochloride	Inhibitor	99.89%	Phase 3
HY-10963	Momelotinib mesylate	Inhibitor	/	Phase 3
HY-15312	WP1066	Inhibitor	99.77%	Phase 2
HY-10193	AZD-1480	Inhibitor	99.91%	Phase 2
HY-13034	Gandotinib	Inhibitor	99.86%	Phase 2
HY-15270	BMS-911543	Inhibitor	98.53%	Phase 2
HY-19631A	Ilginatinib	Inhibitor	99.94%	Phase 2
HY-112708A	Brepocitinib P-Tosylate	Inhibitor	99.86%	Phase 2
HY-130247	Flonoltinib	Inhibitor	99.79%	Phase 2
HY-109179	Itacnosertib	Inhibitor	99.06%	Phase 2
HY-19631B	Ilginatinib hydrochloride	Inhibitor	98.92%	Phase 2
HY-19631	Ilginatinib maleate	Inhibitor	99.87%	Phase 2
HY-156961	GLPG3667	Inhibitor	99.81%	Phase 2
HY-130247A	Flonoltinib TFA	Inhibitor	99.77%	Phase 2
HY-10058	AT9283 lactic acid	Inhibitor	/	Phase 2
HY-15504	RGB-286638	Inhibitor	99.70%	Phase 1
HY-101024	PF-06263276	Inhibitor	99.38%	Phase 1
HY-15504A	RGB-286638 free base	Inhibitor	98.07%	Phase 1
HY-112809	GSK2646264	Inhibitor	98.39%	Phase 1

Pre-clinical Phase

Bioactive Molecules (86)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-148748	Butyzamide	Activator	99.62%	Unkown
HY-18960	CHZ868	Inhibitor	99.56%	Unkown
HY-N1405	Cucurbitacin I	Inhibitor	99.44%	Unkown
HY-14435	Pyridone 6	Inhibitor	98.13%	Unkown
HY-15166	(E/Z)-Zotiraciclib	Inhibitor	99.96%	Unkown
HY-15480	NSC 42834	Inhibitor	98.01%	Unkown
HY-N2963	Broussonin E	Activator	98.18%	Unkown
HY-10410	TG101209	Inhibitor	99.22%	Unkown
HY-10411	AZ960	Inhibitor	97.08%	Unkown
HY-15343	CEP-33779	Inhibitor	99.77%	Unkown
HY-14722	NVP-BSK805	Inhibitor	99.89%	Unkown
HY-145696	SJ10542	Inhibitor	99.92%	Unkown
HY-151902	SJ988497	Inhibitor	98.05%	Unkown
HY-137756	JAK2-IN-6	Inhibitor	99.14%	Unkown
HY-100895	SAR-20347	Inhibitor	97.12%	Unkown
HY-146186	JAK2 JH2 binder-1	Modulator	95.47%	Unkown
HY-108264	TCS 21311	Inhibitor	99.18%	Unkown
HY-N1356	Reticuline	Inhibitor	98.91%	Unkown
HY-113573	Protosappanin A		99.98%	Unkown
HY-14722A	NVP-BSK805 dihydrochloride	Inhibitor	99.36%	Unkown
HY-151262	JAK-IN-23	Inhibitor	98.90%	Unkown
HY-19544	JAK3-IN-1	Inhibitor	99.31%	Unkown
HY-115452	G5-7	Inhibitor	99.55%	Unkown
HY-15166B	(E/Z)-Zotiraciclib citrate	Inhibitor	98.06%	Unkown
HY-147330B	SJ1008030 formic	Inhibitor	97.66%	Unkown
HY-15166A	(E/Z)-Zotiraciclib hydrochloride	Inhibitor	99.90%	Unkown
HY-124858	SC99	Inhibitor	98.96%	Unkown
HY-147330A	SJ1008030 TFA	Inhibitor	99.81%	Unkown
HY-111750	JAK-IN-3	Inhibitor	98.92%	Unkown
HY-131906	JAK2-IN-7	Inhibitor	99.15%	Unkown
HY-120469	2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	Inhibitor	99.80%	Unkown
HY-113787	(R)-9b	Inhibitor	99.51%	Unkown
HY-139423	JAK1-IN-8	Inhibitor	≥95.0%	Unkown
HY-116505	JAK1-IN-4	Inhibitor	99.26%	Unkown
HY-13961	GLPG0634 analog	Inhibitor	98.07%	Unkown
HY-150720	TYK2-IN-12	Inhibitor	98.81%	Unkown
HY-143444	JAK-IN-20	Inhibitor	99.63%	Unkown
HY-152080	TUL01101	Inhibitor	99.71%	Unkown
HY-112391	SD-1029	Inhibitor	/	Unkown
HY-161618	MJ04	Inhibitor	/	Unkown
HY-124727	ZT55	Inhibitor	99.51%	Unkown
HY-148060	JAK-IN-21	Inhibitor	99.72%	Unkown
HY-153440	JAK-IN-25	Inhibitor	98.44%	Unkown
HY-162248	JAK1/2-IN-1	Inhibitor	98.36%	Unkown
HY-107595	SD-1008	Inhibitor	/	Unkown
HY-14722C	NVP-BSK805 trihydrochloride	Inhibitor	/	Unkown
HY-149296	JAK1-IN-12	Inhibitor	/	Unkown
HY-108342	PF-00956980	Inhibitor	/	Unkown
HY-157121	JAK-IN-34	Inhibitor	/	Unkown
HY-161684	JAK2-IN-10	Inhibitor	/	Unkown
HY-151258	TK4g	Inhibitor	/	Unkown
HY-146727	JAK3-IN-11	Inhibitor	/	Unkown
HY-162885	YSY01A	Degrader	/	Unkown
HY-170772	Dual Cathepsin L/JAK-IN-1	Inhibitor	/	Unkown
HY-149283	JAK/HDAC-IN-2	Inhibitor	/	Unkown
HY-169326S	JAK2-IN-11	Inhibitor	/	Unkown
HY-155746	JAK2-IN-9	Inhibitor	/	Unkown
HY-151259	TK4b	Inhibitor	/	Unkown
HY-144440	JAK1-IN-9	Inhibitor	/	Unkown
HY-151285	JAK-2/3-IN-3	Inhibitor	/	Unkown
HY-161967	JAK2/FLT3-IN-3	Inhibitor	/	Unkown
HY-161139	JAK1-IN-14	Inhibitor	/	Unkown
HY-168269	Tyk2-IN-20	Inhibitor	/	Unkown
HY-143884	JAK2/TYK2-IN-1	Inhibitor	/	Unkown
HY-167846	YLIU-4-105-1	Inhibitor	/	Unkown
HY-143885	JAK1/TYK2-IN-3	Inhibitor	/	Unkown
HY-151256	JAK-2/3-IN-2	Inhibitor	/	Unkown
HY-P10840	Tkip	Inhibitor	/	Unkown
HY-W064657	Momelotinib dihydrochloride	Inhibitor	/	Unkown
HY-147754	JAK3/BTK-IN-6	Inhibitor	/	Unkown
HY-117810	JAK2-IN-1	Inhibitor	/	Unkown
HY-18293	NSC 33994	Inhibitor	/	Unkown
HY-10652	JAK-2/3-IN-1	Inhibitor	/	Unkown
HY-100849	JAK 3i	Inhibitor	/	Unkown
HY-154994	JAK-IN-30	Inhibitor	/	Unkown
HY-155951	JAK3-IN-14	Inhibitor	99.32%	Unkown
HY-170723	JAK-IN-39	Inhibitor	/	Unkown
HY-147975	JAK3-IN-12	Inhibitor	/	Unkown
HY-162862	JAK-IN-38	Inducer	/	Unkown
HY-130247B	Flonoltinib monomaleate	Inhibitor	/	Unkown
HY-123187	AS2553627	Inhibitor	/	Unkown
HY-129679	NMS-P953	Inhibitor	/	Unkown
HY-162862	JAK-IN-38	Inhibitor	/	Unkown
HY-163653	Zemprocitinib	Inhibitor	99.31%	Unkown
HY-164393	ON044580	Inhibitor	/	Unkown
HY-119009	TM-233	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Jak2	NCBI	NCBI:3717

Name
Email *

	Sorry, but the email address you supplied was invalid.